The analgesic effects of tryptophan and its metabolites in the rat

Pharmacological Research

Volumn 38, Issue 4, 1998, Pages 243-250

  Heyliger, Simone O ^a   Goodman, Carl B ^a   Ngong, Josephine M ^a   Soliman, Karam F A ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Analgesia; Kynurenic acid; Kynurenine; Quinolinic acid

Indexed keywords

ANTHRANILIC ACID METHYL ESTER; DRUG METABOLITE; ESSENTIAL AMINO ACID; KYNURENIC ACID; KYNURENINE; PICOLINIC ACID; QUINOLINIC ACID; TRYPTOPHAN; XANTHURENIC ACID;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HOT PLATE TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

EID: 0032189162     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0362     Document Type: Article

References (34)

1. 1. King BB. Pain and tryptophan. J Neurosurg 1980; 53: 44-52.
2. 2. Lieberman HR, Corkin S, Spring BJ, Growdon JH, Wurtman RJ. Mood, performance, and pain sensitivity: changes induced by food constituents. J Psychiatr Res 1982; 17: 135-45.
3. 3. During MJ, Heyes MP, Freese A, Markey SP, Martin JB, Roth RH. Quinolinic acid concentrations in striatal extracellular fluid reach potentially neurotoxic levels following systemic L-tryptophan loading. Brain Res 1988; 476: 384-7.
4. 4. Heyes MP, Markey SP. Quantification of quinolinic acid in rat brain, whole blood and plasma by gas chromatography and negative chemical ionization mass spectrometry: Effects of systemic L-tryptophan administrations on brain and blood quinolinic acid concentrations. Anal Biochem 1988; 174: 349-59.
5. 5. Allegri G, Costa C, Baccichetti F, Biasiolo M. Effects of two different loading doses of L-tryptophan on the urinary excretion of tryptophan metabolites in rats, mice and guinea pig. Correlation with enzyme activities. Ital J Biochem 1987; 36: 194-203.
6. 6. Swartz KJ, During MJ, Freese A, Beal MF. Cerebral synthesis and release of kynurenic acid: An endogenous antagonist of excitatory amino acid receptors. J Neurosci 1990; 10: 2965-73.
7. 7. During MJ, Freese A, Heyes MP, Swartz KJ, Markey SP, Roth RH, Martin JB. Neuroactive metabolites of L-tryptophan, serotonin and quinolinic acid, in striatal extracellular fluid: Effect of tryptophan loading. FEBS Lett 1989; 247: 438-44.
8. 8. Moroni F, Lombardi G, Monetti G, Aldino C. The excitotoxin quinolinic acid is present in the brain of several mammals and its content increases during the aging process. Neurosci Lett 1984; 47: 51-5.
9. 9. Wolfensberg M, Ansler U, Cuenod M, Foster AC, Whetsell WO, Schwarcz R. Identification of quinolinic acid in rat and human brain. Neurosci Lett 1983; 41: 247-457.
10. 10. Godefroy F, Matson WR, Gamache PH, Weil-Fugazza J. Simultaneous measurements of tryptophan and its metabolites, kynurenine and serotonin, in the superficial layers of the spinal dorsal horn. A study in normal and arthritic rats. Brain Res 1990; 526: 169-72.
11. 11. Moroni F, Lombardi G, Carla V, Monetti G. The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain. Brain Res 1984; 295: 352-5.
12. 12. Moroni F, Russi P, Lombardi G, Beni M, Carla V. Presence of kynurenic acid in mammalian brain. J Neurochem 1988; 51: 177-80.
13. 13. Chiarugi A, Carpendo R, Moroni F. Kynurenine di-position in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem 1996; 67: 692-8.
14. 14. Lapin IP. Stimulant and convulsive effects of kyneurnines injected into brain ventricles in mice. J Neural Transm 1978; 42: 37-43.
15. 15. Beal MF, Kowal NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986; 321: 168-71.
16. 16. Bruyn RP, Stoof JC. The quinolinic hypothesis in Huntington's chorea. J Neurol Sci 1990; 95: 29-38.
17. 17. Freese A, Swartz KJ, During MJ, Martin JB. Kynurenine metabolites of tryptophan: Implications for neurologic diseases. Neurology 1990; 40: 691-5.
18. 18. Jaquet YF. The NMDA receptor: Central role in pain inhibition in rat periaqueductal gray. Eur J Pharmacol 1988; 154: 271-6.
19. 19. Krieger I, Cash R, Evans GW. Picolinic acid in acrodermatitis enterpathica: evidence for a disorder of tryptophan metabolism. J Pediatr Gastroenterol Nutr 1984; 3: 62-8.
20. 20. Pinelli A, Ossi C, Colombo R, Tofanetti O, Spazzi L. Experimental convulsions in rats induced by intraventricular administration of kynurenine and structurally related compounds. Neuropharmacology 1984; 23: 333-7.
21. 21. Eddy NB, Leimbach D. Systemic: 11 Diethylbutenyl and dithienylbutylamines. J Pharmacol Exp Ther 1953; 107: 385-93.
22. 22. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 74-9.
23. 23. Scheffe HA. A method of judging all contrasts in the analysis of variance. Biometrika 1953; 40: 87-104.
24. 24. SAS/STAT. User's Guide, release 6.12 edition. Cary, NC: SAS Institute, 1996.
25. 25. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J Neurochem 1991; 56: 2007-17.
26. +-independent transporter of neutral amino acids in astrocytes. J Neurosci 1989; 9: 2066-72.
27. 27. Speciale C, Ungerstedt U, Schwarcz R. Effect of kynurenine loading on quinolinic acid production in the rat: studies in vitro and in vivo. Life Sci 1988; 43: 777-86.
28. 28. Perkins MN, Stone TW. Quinolinic acid: Regional variations in neuronal sensitivity. Brain Res 1983; 259: 172-3.
29. 29. Foster AC, Miller LP, Oldendorf WH, Schwarcz R. Studies on the disposition of quinolinic acid after intracerebral or administration in the rat. Exp Neurol 84: 428-40.
30. 30. Kitt TM, Spector R. Transport of quinolinic acid into rabbit and rat brain. Neurochem Res 1987; 12: 625-8.
31. 31. Ruzicka BB, Jhamandas K. Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following focal injection of excitotoxins. Brain Res 1990; 536: 227-39.
32. 32. Naoi M, Ishiki R, Nomura Y, Hasegawa S, Nagatsu T. Quinolinic acid: An endogenous inhibitor specific for type B monoamine oxidase in human synaptosomes. Neurosci Lett 1987; 74: 232-6.
33. 33. Charlton KG, Johnson TD, Clarke DE. Vasoconstrictor and norepinephrine potentiating action of 5-hy droxykynuramine in the isolated perfused rat kidney: Involvement of serotonin receptors and alpha1-adrenoceptors. Naunyn-Schmiedberg's Arch Pharmacol 1984; 328: 154-9.
34. 34. Charlton KG, Johnson TD, Hamed At, Clarke DE. Cardiovascular actions of kynuramine and 5-hydroxykynuramine in pithed rats. J Neuro Transm 1983; 57: 199-211.